CureVac Statistics
Total Valuation
CureVac has a market cap or net worth of $1.21 billion. The enterprise value is $778.06 million.
| Market Cap | 1.21B |
| Enterprise Value | 778.06M |
Important Dates
The next estimated earnings date is Thursday, August 14, 2025, before market open.
| Earnings Date | Aug 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CureVac has 225.17 million shares outstanding. The number of shares has increased by 0.20% in one year.
| Current Share Class | 225.17M |
| Shares Outstanding | 225.17M |
| Shares Change (YoY) | +0.20% |
| Shares Change (QoQ) | +0.31% |
| Owned by Insiders (%) | 5.56% |
| Owned by Institutions (%) | 16.97% |
| Float | 125.87M |
Valuation Ratios
The trailing PE ratio is 6.21.
| PE Ratio | 6.21 |
| Forward PE | n/a |
| PS Ratio | 2.13 |
| Forward PS | 20.14 |
| PB Ratio | 1.73 |
| P/TBV Ratio | 1.80 |
| P/FCF Ratio | 7.02 |
| P/OCF Ratio | 7.14 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 2.99, with an EV/FCF ratio of 4.51.
| EV / Earnings | 3.98 |
| EV / Sales | 1.37 |
| EV / EBITDA | 2.99 |
| EV / EBIT | 3.15 |
| EV / FCF | 4.51 |
Financial Position
The company has a current ratio of 7.65, with a Debt / Equity ratio of 0.06.
| Current Ratio | 7.65 |
| Quick Ratio | 7.33 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | 0.15 |
| Debt / FCF | 0.23 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 33.04% and return on invested capital (ROIC) is 24.37%.
| Return on Equity (ROE) | 33.04% |
| Return on Assets (ROA) | 19.93% |
| Return on Invested Capital (ROIC) | 24.37% |
| Return on Capital Employed (ROCE) | 33.54% |
| Revenue Per Employee | $575,829 |
| Profits Per Employee | $198,637 |
| Employee Count | 983 |
| Asset Turnover | 0.73 |
| Inventory Turnover | 4.85 |
Taxes
In the past 12 months, CureVac has paid $30.76 million in taxes.
| Income Tax | 30.76M |
| Effective Tax Rate | 13.61% |
Stock Price Statistics
The stock price has increased by +59.88% in the last 52 weeks. The beta is 2.49, so CureVac's price volatility has been higher than the market average.
| Beta (5Y) | 2.49 |
| 52-Week Price Change | +59.88% |
| 50-Day Moving Average | 4.17 |
| 200-Day Moving Average | 3.41 |
| Relative Strength Index (RSI) | 65.00 |
| Average Volume (20 Days) | 2,151,040 |
Short Selling Information
The latest short interest is 2.60 million, so 1.16% of the outstanding shares have been sold short.
| Short Interest | 2.60M |
| Short Previous Month | 4.20M |
| Short % of Shares Out | 1.16% |
| Short % of Float | 2.07% |
| Short Ratio (days to cover) | 1.37 |
Income Statement
In the last 12 months, CureVac had revenue of $566.04 million and earned $195.26 million in profits. Earnings per share was $0.87.
| Revenue | 566.04M |
| Gross Profit | 495.98M |
| Operating Income | 246.84M |
| Pretax Income | -297.84M |
| Net Income | 195.26M |
| EBITDA | 260.34M |
| EBIT | 246.84M |
| Earnings Per Share (EPS) | $0.87 |
Balance Sheet
The company has $473.77 million in cash and $40.40 million in debt, giving a net cash position of $433.37 million or $1.92 per share.
| Cash & Cash Equivalents | 473.77M |
| Total Debt | 40.40M |
| Net Cash | 433.37M |
| Net Cash Per Share | $1.92 |
| Equity (Book Value) | 698.97M |
| Book Value Per Share | 3.10 |
| Working Capital | 440.78M |
Cash Flow
In the last 12 months, operating cash flow was $169.73 million and capital expenditures -$10.51 million, giving a free cash flow of $172.65 million.
| Operating Cash Flow | 169.73M |
| Capital Expenditures | -10.51M |
| Free Cash Flow | 172.65M |
| FCF Per Share | $0.77 |
Margins
Gross margin is 87.62%, with operating and profit margins of 43.61% and 34.50%.
| Gross Margin | 87.62% |
| Operating Margin | 43.61% |
| Pretax Margin | 39.93% |
| Profit Margin | 34.50% |
| EBITDA Margin | 45.99% |
| EBIT Margin | 43.61% |
| FCF Margin | 30.50% |
Dividends & Yields
CureVac does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.20% |
| Shareholder Yield | -0.20% |
| Earnings Yield | 16.12% |
| FCF Yield | 14.25% |
Analyst Forecast
The average price target for CureVac is $6.83, which is 26.95% higher than the current price. The consensus rating is "Hold".
| Price Target | $6.83 |
| Price Target Difference | 26.95% |
| Analyst Consensus | Hold |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | -13.76% |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CureVac has an Altman Z-Score of 3.87 and a Piotroski F-Score of 6.
| Altman Z-Score | 3.87 |
| Piotroski F-Score | 6 |